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Antigen-specific T cells represent a potential thera-
peutic avenue for a variety of conditions, but current
approaches for generating such cells for therapeutic
purposes are limited. In this study, we established
iPSCs from mature cytotoxic T cells specific for the
melanoma epitope MART-1. When cocultured with
OP9/DLL1 cells, these iPSCs efficiently generated
TCRb+CD4+CD8+ double positive (DP) cells express-
ing a T cell receptor (TCR) specific for the MART-1
epitope. Stimulation of these DP cells with anti-CD3
antibody generated a large number of CD8+ T cells,
and more than 90% of the resulting cells were
specific for the original MART-1 epitope. Stimulation
of the CD8+ T cells with MART-1 antigen-presenting
cells led to the secretion of IFNg, demonstrating their
specific reactivity. The present study therefore illus-
trates an approach for cloning and expanding func-
tional antigen-specific CD8+ T cells that might be
applicable in cell-based therapy of cancer.
Induced pluripotent stem cells (iPSCs) can be produced from
various types of somatic cells by reprogramming via the Yama-
naka factors (Oct4, Sox2, Klf4, and c-Myc) (Takahashi and
Yamanaka, 2006; Takahashi et al., 2007; Grskovic et al., 2011).
iPSCs are reported to be very similar to embryonic stem cells
(ESCs) in many respects, including gene expression pattern
and pluripotent characteristics. Because iPSCs are not subject
to the same ethical concerns as ESCs, they have great potential
as a major cell source for the production of various types of cells
or organs in regenerative medicine.
One of the possible applications of iPSCs is to use them as
a cell source for producing lymphocytes for cell-based therapyagainst cancer. Immunotherapy approaches to treat cancer
have already been widely applied in clinical settings. Most of
the approaches employed aim to activate tumor-specific cyto-
toxic T lymphocytes (CTLs), which are phenotypically character-
ized as CD3+CD4CD8+ (CD8 single positive: CD8SP) cells
(Sensi and Anichini, 2006). Although the resulting activated
CTLs exhibit some efficacy in killing tumor cells, in most cases
this effect is not sufficiently substantial to cure the patient. A
major limiting factor in this type of approach is the short life
span of activated CTLs, which are inactivated quite rapidly by
antigen-induced cell death (Mescher et al., 2007; Willimsky
and Blankenstein, 2005).
It seemed to us that the application of iPSC technology to
clone and expand tumor antigen-specific T cells could poten-
tially address this issue. Previous studies have reported suc-
cessful reprogramming of mature T cells and B cells using
nuclear transfer, leading to the production of cloned mice that
provided formal proof that the nucleus of a mature somatic cell
can be completely reprogrammed (Hochedlinger and Jaenisch,
2002; Watarai et al., 2010b). Thus far, reprogramming of mature
lymphocytes into iPSCs has been successfully accomplished for
murine B cells (Hanna et al., 2008; Wada et al., 2011), for murine
T cells (Watarai et al., 2010a), and for human T cells (Loh et al.,
2010; Seki et al., 2010). Concurrently, we have developed
methods for differentiating lymphocytes from iPSCs that were
derived from a lymphocyte. In mice, we have already demon-
strated success with this approach using mature NKT cells (Wa-
tarai et al., 2010a).
The previous studies that succeeded in producing iPSCs
from human T cells used whole peripheral mononuclear cells
or CD3+ cells as a source (Loh et al., 2010; Seki et al., 2010).
Therefore, it remains to be shown that isolated CTLs can be re-
programmed to form iPSCs. Initially, therefore, we investigated
the reprogramming of CD8+ T cells isolated from human cord
blood and adult peripheral blood by a cell sorter (Figure S1A
available online). Whole CD3+ cells, as well as non-T cells, i.e.,
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Figure 1. Generation of iPSCs from MART-1-Specific CD8+ T Cell Line JKF6
(A) Flow cytometric profile of JKF6 cells. Cells were stained in two colors with anti-CD3 and MART-1-tetramer.
(B and C) Colony shape analysis (B) and immunofluorescence analysis (C) for the expression of TRA-1-60, TRA-1-81, NANOG, OCT3/4, SSEA3, or SSEA4 in
iPSCs derived from MART-1 epitope-specific T cells (hi70-2) or hESCs (KhES-3). hESCs were used as a control.
(legend continued on next page)
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Antigen-Specific T Cells from Human iPSCscells (Figure S1B), were also used as cell sources. The isolated
T cells were also activated by receiving stimulation from anti-
CD3 and anti-CD28 monoclonal antibodies. On day 1, cells
were infected with Sendai virus (Fusaki et al., 2009) carrying
the four Yamanaka factors (Klf4, Sox2, Oct4, and c-Myc) and
SV40 (large T Antigen) (Park et al., 2008). The resulting colonies
were picked up between day 21 and day 35 for expansion (Fig-
ure S1C). Eventually the colonies generated from T cells showed
a morphology that is almost identical to that of typical human
ESC (hESC) colonies (Figure S1D). The iPSCs expressed charac-
teristic ESC markers such as SSEA4, TRA-1-60, and TRA-1-81.
We designated the iPSCs derived from CD34+ cord blood cells,
whole CD3+ T cells, and CD8+ T cells as hCB-iPSCs, hT-iPSCs,
and hCD8-iPSCs, respectively.
To confirm that the hT-iPSCs and hCD8-iPSCs are derived
from T cells, we analyzed the rearrangement status of TCRb
chain gene by determining the sequence of TCRVb region. In
all cases, rearranged constructs were detected (Figure S1E),
indicating that the cells were derived from T cells. We also exam-
ined whether hCD8-iPSCs are able to produce T lineage cells by
coculturing them with OP9 and then OP9/DLL1 stromal cells
(Figure S2A) (Timmermans et al., 2009; Vodyanik and Slukvin,
2007), with comparison to hESCs and hCB-iPSCs as controls.
Approximately on day 40, CD4+CD8+ double positive (DP) cells
were generated in all three groups (Figure S2B). Although the
flow cytometric profiles of CD4 versus CD8 expression were
almost indistinguishable among the three groups, the proportion
of TCRb+CD3+ cells in DP cells from hCD8-iPSCs was much
higher than in the other groups (Figure S2C). These results
indicate that iPSCs bearing rearranged TCR genes are able to
efficiently give rise to TCR-expressing cells at the preselection
stage.
We then applied these findings to generate iPSCs from
antigen-specific T cells. Because our overall goal is to regen-
erate T cells that can be used for cell-based therapy against
cancer, as a cell source we selected CTLs specific for the mela-
noma epitope MART-1. JKF6 cells are long-term cultured tumor
infiltrated lymphocytes that were originally derived from a mela-
noma patient and have beenmaintained at the Surgery Branch of
the National Cancer Institute (Yang et al., 2011). JKF6 cells spe-
cifically recognize a complex of the MART-1-peptide and the
HLA-A*02:01 molecule, which can be detected using MART-1-
tetramer by flow cytometry (Figure 1A).
MART-1-specific T cells were transduced with the Yamanaka
factors using the same approach as shown in Figure S1C.
Approximately 20 colonies were generated from 5 3 105 JKF
cells, and we picked up 10 colonies out of them. Among them,(D) The expression of hESC marker genes in hi70-2, JKF6, or KhES-3 cells.
(E) Flow cytometric profile of JKF6 cells and hi70-2 cells for the expression of CD
(F) Expression profiles of SeV-derivedOCT3/4, SOX2, KLF4, c-MYC, and SV40 in h
used as a control.
(G) Comparison of global gene expression of hi70-2 cells against that of khES3 o
signals were present (n) are shown in each scatter plot.
(H) Representative three germ layers (mesoderm, ectoderm, and endoderm) deve
subcutaneous injection of hi70-2 cells to nude mice, were stained with hematox
(I) Karyotype analysis of hi70-2 cells.
(J) The sequence of rearranged TCRa or TCRb chain gene in hi70-2 or JKF6 cell
(K) PCR analysis of rearranged TCRa or TCRb chain gene in hi70-2, JKF6, or Kh
See also Figure S1 and Table S1.two were analyzed for the rearrangement status of TCRb chain
gene, and both were found to carry the rearranged configuration
of the gene that was the same as the one found in JKF cells.
Hereafter we focus on one of these two clones, clone hi70-2,
for further experiments. hi70-2 cells formed a colony exhibiting
hESC-like morphology (Figure 1B). hi70-2 cells were positive
for TRA-1-60, TRA-1-81, OCT3/4, NANOG, SSEA3, and SSEA4
by immunofluorescence staining (Figure 1C). RT-PCR analysis
showed that hi70-2 cells are positive for endogenous OCT3/4,
SOX2, KLF4, and c-MYC, as well as other ESC markers, while
negative for the T cell marker CD3ε (Figure 1D). We also
confirmed the loss of the T cell markers CD3 and CD8 by flow cy-
tometry (Figure 1E). SeV-derived OCT3/4, SOX2, KLF4, c-MYC,
or SV40 was not expressed in these cells (Figure 1F). Global
gene expression analysis by microarray showed more similarity
between hi70-2 cells and hESCs than the original CTLs (Fig-
ure 1G). We further showed that hi70-2 cells are able to form
teratomas with three germ layers upon subcutaneous injection
into nude mice (Figure 1H). Karyotype analysis showed that the
cells have no chromosomal abnormalities (Figure 1I). We thus
concluded that hi70-2 cells represent human iPSCs. We finally
examined the rearrangement status of TCRa and b chain genes
of hi70-2 cells and found that they retain the same rearranged
configuration as original JKF6 cells (Figures 1J and 1K). These
results demonstrated that MART-1-specific T cells were
successfully reprogrammed to iPSCs. Hereafter the hi70-2 cells
are designated as ‘‘MART-1-iPSCs.’’
To examine whether MART-1-iPSCs are able to differen-
tiate into mature T cells, we cultured them with OP9 and
subsequently with OP9/DLL1 stromal cells as described in Fig-
ure S2A. As controls, hESCs, hCB-iPSCs, and hCD8-iPSCs
were also cultured. In all four groups, CD34+CD43+ cells, repre-
senting very early hematopoietic progenitors (Vodyanik et al.,
2006), were generated on day 13 (Figure 2A). At this time point,
CD34+CD43+ cells from all four groups had comparable capacity
to produce myeloid and erythroid cells in colony-forming assays
(Figure 2B).
On day 40, CD4+CD8+ DP cells were generated in all four
groups (data not shown). The majority of the DP cells generated
from MART-1-iPSCs expressed TCR specific to the MART-1
epitope, although about 30% of CD3+ DP cells were negative
or only weakly positive forMART-1-tetramer staining (Figure 2C).
In a physiological context, MART-1-specific T cells could be
positively selected by thymic cortical epithelial cells that express
a complex of HLA-A*02:01 and positively-selecting peptides
distinct from the MART-1 epitope. However, with current tech-
nology it is difficult to reproduce positive selection based on3 versus CD8.
i70-2, JKF6, or KhES-3 cells. SeV-transfected cells (2 days after infection) were
r JKF6 cells. Pearson’s correlation coefficient (r) and number of probes whose
loped in hi70-2 cells. Histological sections of teratomas, formed 4 weeks after
ylin and eosin.
s.
ES-3 cells.
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Figure 2. Regeneration of Antigen-Specific CD8SP Mature T Cells in an In Vitro Culture from hT-iPSCs
(A) Generation of hematopoietic progenitor cells from iPSCs of different origins. A cluster of human iPSC colonies was cut into small clumps and plated on
a monolayer of OP9 stromal cells. On day 13, cells were harvested by tripsinization and stained for the expression of CD34 versus CD43.
(legend continued on next page)
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Antigen-Specific T Cells from Human iPSCsthe MHC-TCR ligation in a monolayer coculture system. For this
approach, we felt that a more straightforward induction would
suffice, particularly as most of the DP cells generated express
a TCR that is specific for the MART-1 epitope. SP cells can be
induced from DP cells with the simple addition of anti-CD3 anti-
body even in the absence of TCR-MHC ligation (Takahama et al.,
1994). Thus, we added anti-CD3 mAb to the culture on day 35,
when DP cells are already abundant. The number of CD8+CD3+
MART-1+ cells increased by 300-fold over the 6 days following
TCR stimulation (Figure 2D). After stimulation, the DP cells
started to decrease on day 1 and were barely detectable by
day 3, when populations of CD4+ and CD8+ T cells became
evident (Figure 2E). This time course suggests that the genera-
tion of CD4+ and CD8+ T cells is not due to the expansion of
pre-existing mature T cells but instead to the induction of matu-
ration from DP into SP T cells. On day 6, the CD4+ T cells disap-
peared and the number of CD8+ T cells increased further (Fig-
ure 2F, middle panel). In the control nonstimulated samples,
the cells remained virtually unchanged (Figure 2F, left panel).
Importantly, the resulting CD8+ T cells were almost exclusively
specific for the MART-1 epitope (Figure 2F, right panel). We
obtained similar findings in nine independent experiments
(Figure 2G). Sequence analysis of TCRa chain mRNA in the re-
generated CD8SP T cells in one of these experiments confirmed
that a large majority of regenerated CD8SP cells bear the same
TCRa chain gene as original MART-1-iPSCs (Figure 2H). By
contrast, CD8SP cells induced from hCD8-iPSCs express virtu-
ally no MART-1-tetramer+ cells (Figure 2I).
We also examined whether the generated CD8SP cells are
functionally mature. MART-1+CD3+CD8+ T cells were isolated
using a cell sorter and stimulated with beads coated with a
mixture of anti-CD3 mAb and anti-CD28 mAb. IFNg production
by the CD8+ T cells was detected following this CD3/CD28 stim-
ulation, and production of IFNg was synergistically enhanced by
the addition of hIL-2 (Figure 2J). To examine whether the CD8+
T cells can be activated in an antigen-specific manner, they
were cocultured with human EBV-lymphoblastoid cell line ex-
pressing HLA-A*02:01 with or without MART-1-peptide for(B) Sorted CD34+CD43+ cells were subjected to CFU-C assay. Average numbers a
stand for colony containing granulocytes and monocytes, granulocytes, monocy
(C) Cells generated from MART-1-iPSCs on day 40 of culture. The proportion of
72.5 ± 11.1 (mean ± SD).
(D) Number of MART-1-specific CD8+ T cells in the culture with or without anti-C
(E) Time course of CD8SP cell generation in an in vitro culture system. CD4 vers
shown.
(F) Efficient generation of antigen-specific mature T cells in vitro from T-iPSCs. Le
without or with TCR stimulation, respectively. Right panel shows the CD3 versus
panel.
(G) Proportion of MART-1-specific T cells in the generated CD8+ T cells. A total of
TCR stimulation in the same manner as in (D), and generated cells were recovered
in a similar manner as that shown in (F). A horizontal bar in the panel represents
95.5%.
(H) Sequence data of TCRa chain gene in CD8SP cells generated from MART-1-
(I) Flow cytometric profile of CD8SP cells generated from hCD8-iPSCs.
(J) Production of IFNg by CD8+ T cells upon TCR stimulation. CD8+ T cells were is
Dynabeads, in the absence or presence of hIL-2. After 16 hr, the concentration o
(K) Production of IFNg by CD8+ T cells upon antigen-specific stimulation. IFNg s
13 105 CD8 SP cells derived fromMART-1-iPSCs with 13 104 HLA-A*02:01-pos
(EAAGIGILTV). Mean ± SE of triplicates is shown.
See also Figure S2.24 hr. The CD8+ T cells produced a substantial amount of IFNg
in the presence of a specific peptide (Figure 2K). Thus, this
iPSC-based approach appears to be effective in regenerating
the functional antigen-specific CTLs.
It is important to note that the proportion of MART-1-specific
T cells in the CD3+ cells population was around 70%–80% in
DP cells, but it became more than 95% in the CD8+ T cells. It is
known that DP cells rearrange their TCRa chain genes several
times unless they get positively or negatively selected (Petrie
et al., 1993). Thus, it is likely that the MART-1-tetramer nega-
tive/low cells in DP cells (Figure 2C) represent cells in which the
inheritedVa-Jagenehasbeendeleted through further rearrange-
ment.Why, then, doMART-1-tetramer+ cells eventually predom-
inate in the CD8+ T cells? One explanationmay come from differ-
ential stability of pairing of TCRa and b chains; the cells that have
formed a new TCR by replacing the original TCRa chain may not
be able to compete with T cells bearing the inherited TCR.
To summarize, we have succeeded in the expansion of
antigen-specific T cells by making iPSCs from T cells and differ-
entiating them back into T cells. Further studies are needed to
determine whether these regenerated mature T cells can kill
cancer cells in vitro or in vivo. It may also be possible to develop
a strategy that avoids the need to produce mature T cells in vitro.
One idea is to produce T cell progenitors from antigen-specific
iPSCs and transfer them to patients, anticipating that the trans-
ferred T cell progenitors would migrate into the thymus and
produce a large number of naive CTLs that are specific for the
tumor antigen. Along these lines, we have developed a coculture
system using murine stromal cells that can be used to expand
T cell progenitors induced from human hematopoietic stem cells
(Meek et al., 2010).We have also developed a feeder-free culture
system that makes it possible to expand mouse early T cell
progenitors in an almost limitless fashion (Ikawa et al., 2010).
If this type of approach is effective, a large number of naive
CTLs bearing tumor-antigen-specific TCR could be generated
in vivo in a patient. Thus, by immunizing the patient with the
tumor antigen, we could expect to see a strong and long-lasting
immune response to the tumor.nd proportions of colony type of triplicate cultures are shown. GM, G, M, and E
tes, and erythroid cells, respectively.
MART-1-tetramer+ cells in CD3+DP cells in six independent experiments was
D3 mAb treatment.
us CD8 profiles of cells before and after TCR stimulation (day 1 and day 3) are
ft and middle panels show CD4 versus CD8 profiles of cells generated on day 6
MART-1-tetramer staining of CD8+ T cells gated in a rectangle in the middle
nine independent experiments were performed. CD8+ T cells were induced by
on indicated days. The proportion of MART-1-specific T cells was determined
an average (96.5%) of five values on day 6. An average of all nine values was
iPSCs in comparison with that in the original MART-1-iPSCs.
olated by a cell sorter and stimulated by adding human T-Activator CD3/CD28
f IFNg in medium was measured by ELISA.
ecretion was measured by ELISA from the supernatant after 24 hr coculture of
itive EBV-lymphoblastoid cells (CIRA0201) pulsed or not with MART-1-peptide
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